GlassScriptPhysician profile
Brooke C Maple
NPI 1780932319
$2,993.75
in general payments reported to CMS, 2019-2025
22 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $147 · 2023: $858 · 2024: $863 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,846.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $416.95 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $372.21 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $354.28 | 2022-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $284.53 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $212.97 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $198.97 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $189.15 | 2023-2025 | Auvelity |
| Novo Nordisk INC | $167.10 | 2025 | Wegovy |
| Neurocrine Biosciences, INC. | $154.73 | 2022-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $151.53 | 2023-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.48 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $80.99 | 2023-2025 | Trintellix |
| Bausch Health US, LLC | $72.87 | 2024-2025 | Aplenzin, Wellbutrin |
| Almatica Pharma LLC | $70.09 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| E.R. Squibb & Sons, L.L.C. | $47.05 | 2024-2025 | Cobenfy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| C2n Diagnostics, LLC | $26.35 | 2025 | Precivityad2 |
| Noven Therapeutics, LLC | $23.06 | 2024 | Xelstrym |
| Vanda Pharmaceuticals INC. | $18.81 | 2022 | |
| Braeburn INC. | $17.64 | 2025 | Brixadi |
| Brainsway USA INC | $15.94 | 2025 | Deep Tms System |
| Indivior INC. | $15.84 | 2024 | Sublocade |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.21 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Maple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.